Trial Profile
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 18 Jan 2023 This trial has been discontinued in Belgium according to European Clinical Trials Database record.
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2020.